Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Shock

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
International Immunopharmacology|December 12, 2018
Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopeniaBryan Smith, Louis Christodoulou, Alison Clargo, et al.
Cellular Immunology|July 1, 2026
The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitroJulija Sirina, Lena E D'Hooghe, Laura A Singhvi-Hanns, et al.
The Journal of Experimental Medicine|December 4, 2002
Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammationGeoffrey John Bellingan, Ping Xu, Helen Cooksley, et al.
Journal of Autoimmunity|May 4, 2020
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseasesSijia Chen, Ross Paveley, Lianne Kraal, et al.
Biochemistry|March 3, 2004
Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetryMatthew P Crump, Thomas A Ceska, Leo Spyracopoulos, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2003
Dehydrophenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 14, 2022
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune EncephalomyelitisJana Remlinger, Adrian Madarasz, Kirsten Guse, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Mabs|January 19, 2024
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells <i>in vitro</i>Omar S Qureshi, Emma J Sutton, Rosemary F Bithell, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Immunopharmacology|December 12, 2018
Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopeniaBryan Smith, Louis Christodoulou, Alison Clargo, et al.
Cellular Immunology|July 1, 2026
The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitroJulija Sirina, Lena E D'Hooghe, Laura A Singhvi-Hanns, et al.
The Journal of Experimental Medicine|December 4, 2002
Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammationGeoffrey John Bellingan, Ping Xu, Helen Cooksley, et al.
Journal of Autoimmunity|May 4, 2020
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseasesSijia Chen, Ross Paveley, Lianne Kraal, et al.
Biochemistry|March 3, 2004
Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetryMatthew P Crump, Thomas A Ceska, Leo Spyracopoulos, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2003
Dehydrophenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 14, 2022
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune EncephalomyelitisJana Remlinger, Adrian Madarasz, Kirsten Guse, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonistsJohn R Porter, Sarah C Archibald, Julien A Brown, et al.
Mabs|January 19, 2024
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells <i>in vitro</i>Omar S Qureshi, Emma J Sutton, Rosemary F Bithell, et al.
Pageof 3